IBD Evidence

Članak

Što uzrokuje IBD? Genetika, okoliš, rast incidencije

Updated 4 min read 60 citations

Žičana endoskopska omča koja se koristi za polipektomiju gornjeg gastrointestinalnog trakta i debelog crijeva
Gilo1969 · CC BY-SA 3.0 · Wikimedia Commons

Ni genetika ni okoliš sami ne objašnjavaju upalnu bolest crijeva. Genetika govori tko je osjetljiv; epidemiologija govori da osjetljivost sama po sebi ne može biti cijela priča, jer se globalna karta bolesti mijenjala previše brzo da bi je geni mogli objasniti.

Što genetika zapravo pokazuje

Studije udruženosti na razini cijelog genoma identificirale su znatan broj lokusa povezanih s osjetljivošću na IBD. Meta-analiza podataka o udruženosti identificirala je 38 lokusa osjetljivosti i istaknula genetski rizik zajednički u različitim populacijama te, što je zanimljivo, djelomično zajednički s drugim imunološki posredovanim bolestima [26]. Druga studija udruženosti na razini cijelog genoma upletala je specifično imunološku aktivaciju više integrinskih gena [25] — mehanistički zanimljiv rezultat, jer lijekovi koji blokiraju integrine (razred anti-integrinskih bioloških lijekova opisan na našoj stranici o liječenju) djeluju upravo prekidanjem puta prometovanja leukocita u kojem se ti geni nalaze.

Praktična poruka genetike uža je nego što se očekuje. IBD nije monogenska, mendelski nasljedna bolest — ona je poligenska, s mnogo lokusa od kojih svaki doprinosi malim dijelom rizika. Imati rođaka prvog stupnja s IBD-om povećava rizik iznad razine opće populacije, ali velika većina ljudi koji nose genetske varijante povezane s IBD-om nikada ne razvije bolest. Genetika postavlja prag osjetljivosti; nešto drugo odlučuje hoće li se taj prag prijeći.

Zašto genetika ne može biti cijela priča

Genetska arhitektura populacije ne mijenja se tijekom nekoliko desetljeća. Globalna incidencija IBD-a jest. Analiza iz 2025. objavljena u Nature prati incidenciju IBD-a kroz faze koje naziva epidemiološkim stadijima — nisku incidenciju, fazu ubrzanja u kojoj incidencija naglo raste, a zatim fazu kompozicijske ravnoteže prevalencije u kojoj incidencija dosegne plato, ali broj ljudi koji žive s bolešću i dalje raste jer je bolest kronična [36]. Regije koje se danas novo industrijaliziraju prolaze kroz fazu ubrzanja kroz koju su Zapadna Europa i Sjeverna Amerika prošle tijekom dvadesetog stoljeća.

Ovaj obrazac dokumentiran je i ranije u sustavnom pregledu populacijskih studija o incidenciji i prevalenciji u svijetu [24], a dodatni pregled koji se posebno bavi epidemiologijom kroz dobne skupine u eri napredne terapije smješta trenutačnu globalnu sliku u kontekst [34]. Sustavni pregled usmjeren na IBD s početkom u dječjoj dobi pronašao je isti trend ubrzanja specifično kod djece i adolescenata [16], a trendovi hospitalizacije u istom razdoblju opisani su u dodatnom sustavnom pregledu s vremenskim analizama [7].

Geografski i vremenski obrazac koji prati industrijalizaciju, a ne genetski zanos, najjači je dostupan argument da nešto u načinu na koji populacija živi — a ne samo u tome kako se rađa — nosi znatan dio uzročnog utjecaja.

Mogući okolišni čimbenici

Krovni pregled meta-analiza izravno je istražio okolišne čimbenike rizika za IBD, objedinjujući dokaze iz brojnih pojedinačnih studija izloženosti u jednu sintezu [21]. Iskren sažetak te literature jest da nekoliko kandidata ima potporne dokaze različite jačine, ali za nijedan nije pokazano da je sam po sebi dovoljan — što je u skladu s bolešću koja vjerojatno zahtijeva da genetski osjetljiv pojedinac naiđe na određenu kombinaciju izloženosti.

Cjelovita slika: kako se dijelovi uklapaju

Kategorija čimbenikaŠto je utvrđenoŠto nije
Genetska osjetljivostIdentificirane su desetke doprinosećih lokusa; rizik se nakuplja u obiteljima i dijeli mehanizme s drugim imunološkim bolestimaNijedan pojedinačni gen nije nužan ni dovoljan; većina genetski osjetljivih osoba nikada ne razvije IBD
Geografski/vremenski obrazacIncidencija naglo raste kako se regije industrijaliziraju, a zatim dosegne plato dok prevalencija i dalje rasteObrazac pokazuje da je okoliš važan; sam po sebi ne otkriva koja je izloženost najvažnija
Pojedinačne okolišne izloženostiKrovni pregled sintetizirao je literaturu o izloženosti kroz mnoge moguće čimbenikeNijedan pojedinačni okolišni čimbenik nije utvrđen kao nužan ili sam po sebi dovoljan
InterakcijaVjerojatna i u skladu s ukupnim obrascem podataka: osjetljivost plus izloženostNije izravno mjerljiva postojećim nacrtima studija na razini pojedinca

Zašto je to praktično važno

Ništa od ovoga ne mijenja liječenje. Ne identificira namirnicu koju treba izbjegavati, promjenu načina života koja bi zajamčeno spriječila pogoršanja, ni test koji predviđa individualni rizik s korisnom preciznošću. Ono što ovo doista objašnjava su dvije stvari o kojima se pacijentima često govori nedosljedno: da IBD nije "uzrokovan" prehranom ili stresom u bilo kojem jednostavnom smislu (genetika i promjene okoliša na razini populacije nose daleko veći dio uzročnog utjecaja od svakodnevnih izbora), te da to također nije čista genetska nesreća (rastuća incidencija u regijama koje se novo industrijaliziraju to sama po sebi isključuje). Oba ta preokvirivanja obično smanjuju osjećaj krivnje koji pacijenti prijavljuju vezano za pitanje "što sam učinio da ovo uzrokujem" — pitanje koje baza dokaza zapravo ne opravdava postavljati u vezi s bilo kojim pojedinačnim ponašanjem.

Često postavljana pitanja

Je li IBD nasljedan? Hoće li moja djeca oboljeti?
Rizik je povećan kod rođaka prvog stupnja osobe s IBD-om, ali velika većina rođaka nikada ne razvije bolest. Radi se o obrascu gena osjetljivosti, a ne o mendelski nasljednoj bolesti.
Je li nešto što sam pojeo ili učinio uzrokovalo moj IBD?
Nijedan pojedinačni čimbenik prehrane ili načina života nije utvrđen kao dovoljan uzrok. Dokazi upućuju na kombinaciju genetske osjetljivosti i okolišnih izloženosti na razini populacije koje se odvijaju kroz godine, a ne na prepoznatljiv individualni okidač.
Zašto IBD postaje sve češći u zemljama u kojima je nekad bio rijedak?
Ovo dovoljno usko prati industrijalizaciju da predstavlja jedan od najjačih argumenata za okolišnu komponentu — geni se ne mijenjaju dovoljno brzo da bi to objasnili, a obrazac je sada dokumentiran u više regija i razdoblja.
Ako genetika objašnjava samo podložnost, što je stvarni pokretač?
Nije precizno utvrđeno. Mogući okolišni čimbenici sintetizirani su u dokazima krovnih pregleda (umbrella review), ali nije pokazano da je ijedan pojedinačni čimbenik nužan ili dovoljan — ovo ostaje otvoreno područje istraživanja, a ne riješeno pitanje.
Tri kamerne kapsule koje se koriste za snimanje jednjaka, tankog i debelog crijeva
Progutane kapsule fotografiraju dijelove tankog crijeva do kojih konvencionalni endoskop ne može doprijeti. Dr.HH.Krause · CC BY-SA 3.0 · Wikimedia Commons

Povezano štivo

Dokazi na kojima se temelji ova stranica Stupčasti grafikon koji prikazuje sastav 36 publikacija citiranih na ovoj stranici prema vrsti studije. 2663meta-analysis (26)randomised trial (6)review (3)other (1)
36 publikacija, 2015.–2026. Riječ je o miješanom skupu koji sadrži i klinička ispitivanja i sinteze, što je pozicija s koje je tvrdnja o uzročnosti opravdana. Izvor: popis citata ove stranice, u nastavku.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Dual biologics or combination therapy with small molecules in pediatric inflammatory bowel disease: a systematic review and meta-analysis Huo BL, Zhao AL, Liu W, et al. · World journal of pediatrics : WJP · 2026 · Meta-analysis DOIPubMed 42387245
  2. Mediterranean diet in treatment of inflammatory bowel disease: A systematic review and meta-analysis Singh A, Rana U, Chandnani S, et al. · Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026 · Meta-analysis DOIPubMed 41803562
  3. Study Design Complexity and Participant Completion in Dietary Trials for Inflammatory Bowel Disease: A Systematic Review and Metaresearch Study Gregersen L, Moos C, Hikmat Z, et al. · Advances in nutrition (Bethesda, Md.) · 2026 · Systematic review DOIPubMed 41825595Full text
  4. Phenotypic Differences in Inflammatory Bowel Diseases Across Race, Ethnicity, and Geography: A Systematic Review of 237 Population-Based Studies Halim A, Ho AHY, Wanchaitanawong W, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026 · Meta-analysis DOIPubMed 41577066
  5. Blood Bile Acids for Inflammatory Bowel Disease Diagnosis and Disease Activity Assessment: A Metabolomics Meta-Analysis Thu NQ, An VT, Dat LHB, et al. · Journal of proteome research · 2026 · Meta-analysis DOIPubMed 42695907
  6. Safety of advanced therapies in pregnant women with inflammatory bowel disease: a systematic review and Meta-Analysis Moraes BF, Leite GAPD, Visentini LM, et al. · Journal of Crohn's & colitis · 2026 · Meta-analysis DOIPubMed 41874976
  7. The Role of Inflammation in Infant Colic-A Systematic Review and Meta-Analysis Andersen DB, Fog J, Vestergaard MV, et al. · Acta paediatrica (Oslo, Norway : 1992) · 2026 · Meta-analysis DOIPubMed 41803938Full text
  8. Management of paediatric ulcerative colitis, part 2: Acute severe colitis-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization Assa A, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40528309
  9. Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation Wine E, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40677018Full text
  10. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn's Disease: 2025 AGA Evidence Synthesis Singh S, Murad MH, Yuan Y, et al. · Gastroenterology · 2025 · Meta-analysis DOIPubMed 41114682Full text
  11. Pre-Illness Index-Based Dietary Patterns and Inflammatory Bowel Disease Risk: A Systematic Review and Meta-Analysis Meng F, Zhang T, Meng X, et al. · Nutrition reviews · 2025 · Meta-analysis DOIPubMed 40700526
  12. Using Diet to Treat Inflammatory Bowel Disease: A Systematic Review Gleave A, Shah A, Tahir U, et al. · The American journal of gastroenterology · 2025 · Systematic review DOIPubMed 39056556
  13. Efficacy of a Low-FODMAP Diet on the Severity of Gastrointestinal Symptoms and Quality of Life in the Treatment of Gastrointestinal Disorders-A Systematic Review of Randomized Controlled Trials Kuźmin L, Kubiak K, Lange E · Nutrients · 2025 · Systematic review DOIPubMed 40573159Full text
  14. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis Ananthakrishnan AN, Murad MH, Scott FI, et al. · Gastroenterology · 2024 · Meta-analysis DOIPubMed 39425738Full text
  15. Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes Zheng T, Roda G, Zabana Y, et al. · Journal of Crohn's & colitis · 2024 · Meta-analysis DOIPubMed 37768647
  16. Acute severe ulcerative colitis trials: the past, the present and the future Honap S, Jairath V, Sands BE, et al. · Gut · 2024 · Systematic review DOIPubMed 38834296Full text
  17. Efficacy of different dietary therapy strategies in active pediatric Crohn's disease: a systematic review and network meta-analysis Ma J, Chong J, Qiu Z, et al. · PeerJ · 2024 · Meta-analysis DOIPubMed 39686992Full text
  18. Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses Buie MJ, Quan J, Windsor JW, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023 · Meta-analysis DOIPubMed 35863682
  19. Single-cell meta-analysis of inflammatory bowel disease with scIBD Nie H, Lin P, Zhang Y, et al. · Nature computational science · 2023 · Meta-analysis DOIPubMed 38177426
  20. Features of paradoxical psoriasis and risk factors in inflammatory bowel disease: A systematic review and meta-analysis Croitoru DO, Brooks SG, Nathanielsz N, et al. · Journal of the European Academy of Dermatology and Venereology : JEADV · 2023 · Meta-analysis DOIPubMed 36912825
  21. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications Russell MD, Stovin C, Alveyn E, et al. · Annals of the rheumatic diseases · 2023 · Meta-analysis DOIPubMed 37247942Full text
  22. High-Fiber Diet and Crohn's Disease: Systematic Review and Meta-Analysis Serrano Fernandez V, Seldas Palomino M, Laredo-Aguilera JA, et al. · Nutrients · 2023 · Meta-analysis DOIPubMed 37513532Full text
  23. Dietary Interventions in Ulcerative Colitis: A Systematic Review of the Evidence with Meta-Analysis Herrador-López M, Martín-Masot R, Navas-López VM · Nutrients · 2023 · Meta-analysis DOIPubMed 37836478Full text
  24. Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs Alrubia S, Mao J, Chen Y, et al. · Clinical pharmacokinetics · 2022 · Meta-analysis DOIPubMed 36056298Full text
  25. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Ahmed W, Galati J, Kumar A, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022 · Meta-analysis DOIPubMed 33798711
  26. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis Lasa JS, Olivera PA, Danese S, et al. · The lancet. Gastroenterology & hepatology · 2022 · Meta-analysis DOIPubMed 34856198
  27. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials Ben-Horin S, Novack L, Mao R, et al. · Gastroenterology · 2022 · Meta-analysis DOIPubMed 34757139
  28. Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review Kuenzig ME, Fung SG, Marderfeld L, et al. · Gastroenterology · 2022 · Systematic review DOIPubMed 34995526
  29. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis Peyrin-Biroulet L, Arkkila P, Armuzzi A, et al. · BMC gastroenterology · 2022 · Meta-analysis DOIPubMed 35676620Full text
  30. Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease Sinopoulou V, Gordon M, Akobeng AK, et al. · The Cochrane database of systematic reviews · 2021 · Systematic review DOIPubMed 34844288Full text
  31. Systematic Review of the Effects of Oat Intake on Gastrointestinal Health Valido E, Stoyanov J, Bertolo A, et al. · The Journal of nutrition · 2021 · Systematic review DOIPubMed 34486656
  32. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome Bolte LA, Vich Vila A, Imhann F, et al. · Gut · 2021 · Meta-analysis DOIPubMed 33811041Full text
  33. Incidence of SARS-CoV-2 infection in inflammatory bowel disease Lee MH, Ng CH, Chin YH, et al. · Journal of gastroenterology and hepatology · 2020 · Meta-analysis DOIPubMed 32779774Full text
  34. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms Kucharzik T, Koletzko S, Kannengiesser K, et al. · Deutsches Arzteblatt international · 2020 · Meta-analysis DOIPubMed 33148393Full text
  35. Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses Piovani D, Danese S, Peyrin-Biroulet L, et al. · Gastroenterology · 2019 · Meta-analysis DOIPubMed 31014995
  36. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis Shigesi N, Kvaskoff M, Kirtley S, et al. · Human reproduction update · 2019 · Meta-analysis DOIPubMed 31260048Full text
  37. ESPEN guideline: Clinical nutrition in inflammatory bowel disease Forbes A, Escher J, Hébuterne X, et al. · Clinical nutrition (Edinburgh, Scotland) · 2017 · Systematic review DOIPubMed 28131521
  38. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies Ng SC, Shi HY, Hamidi N, et al. · Lancet (London, England) · 2017 · Systematic review DOIPubMed 29050646
  39. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease de Lange KM, Moutsianas L, Lee JC, et al. · Nature genetics · 2017 · Meta-analysis DOIPubMed 28067908Full text
  40. Inflammatory bowel disease and risk of stroke: A meta-analysis of cohort studies Yuan M, Zhou HY, Xiao XL, et al. · International journal of cardiology · 2016 · Meta-analysis DOIPubMed 26386936
  41. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS Menees SB, Powell C, Kurlander J, et al. · The American journal of gastroenterology · 2015 · Meta-analysis DOIPubMed 25732419
  42. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations Liu JZ, van Sommeren S, Huang H, et al. · Nature genetics · 2015 · Meta-analysis DOIPubMed 26192919Full text
  43. Consumption of vegetables and fruit and the risk of inflammatory bowel disease: a meta-analysis Li F, Liu X, Wang W, et al. · European journal of gastroenterology & hepatology · 2015 · Meta-analysis DOIPubMed 25831134
  44. Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis Zhou XL, Xu W, Tang XX, et al. · BMC gastroenterology · 2014 · Meta-analysis DOIPubMed 25002150Full text
  45. Effect of Five Dietary Emulsifiers on Inflammation, Permeability, and the Gut Microbiome: A Placebo-controlled Randomized Trial Wellens J, Vanderstappen J, Hoekx S, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026 · Randomised controlled trial DOIPubMed 40816342
  46. A Randomised Controlled Trial Comparing the Effects of Personalised Diet and Physical Activity Intervention Versus Usual Care on Cardiometabolic Risk Factors in Adults with Inactive Inflammatory Bowel Disease Yap JM, Wall CL, Meredith-Jones K, et al. · Nutrients · 2026 · Randomised controlled trial DOIPubMed 41829955Full text
  47. Evidence for a Modulatory Effect of a 12-Week Pomegranate Juice Intervention on the Transcriptional Response in Inflammatory Bowel Disease Patients Reducing Fecal Calprotectin Levels: Findings From a Proof-of-Principle Study Minato I, Mena P, Ricciardiello L, et al. · Molecular nutrition & food research · 2025 · Randomised controlled trial DOIPubMed 40255128Full text
  48. Effects of bromelain supplementation on disease activity and quality of life in patients with ulcerative colitis: a randomized, triple-blind, placebo-controlled study Delgarm P, Mokhtare M, Ebrahimi Daryani N, et al. · Scientific reports · 2025 · Randomised controlled trial DOIPubMed 41315628Full text
  49. Whole Food Diet Induces Remission in Children and Young Adults With Mild to Moderate Crohn's Disease and Is More Tolerable Than Exclusive Enteral Nutrition: A Randomized Controlled Trial Aharoni-Frutkoff Y, Plotkin L, Pollak D, et al. · Gastroenterology · 2025 · Randomised controlled trial DOIPubMed 40553742
  50. The use of the Crohn's disease exclusion diet (CDED) in adults with Crohn's disease: A randomized controlled trial Pasta A, Formisano E, Calabrese F, et al. · European journal of clinical investigation · 2025 · Randomised controlled trial DOIPubMed 39853756
  51. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study Ferrante M, D'Haens G, Jairath V, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 39581202
  52. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial Yanai H, Levine A, Hirsch A, et al. · The lancet. Gastroenterology & hepatology · 2022 · Randomised controlled trial DOIPubMed 34739863
  53. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial Cox SR, Lindsay JO, Fromentin S, et al. · Gastroenterology · 2020 · Randomised controlled trial DOIPubMed 31586453
  54. Treatment of Active Crohn's Disease With an Ordinary Food-based Diet That Replicates Exclusive Enteral Nutrition Svolos V, Hansen R, Nichols B, et al. · Gastroenterology · 2019 · Randomised controlled trial DOIPubMed 30550821
  55. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial Levine A, Wine E, Assa A, et al. · Gastroenterology · 2019 · Randomised controlled trial DOIPubMed 31170412
  56. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. · The New England journal of medicine · 2019 · Randomised controlled trial DOIPubMed 31553834
  57. Chronic, Noninfectious Diarrhea: A Review Singh P, Lee A, Sheth NM, et al. · JAMA · 2026 · Review DOIPubMed 41770539
  58. Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies Caron B, Honap S, Peyrin-Biroulet L · Journal of Crohn's & colitis · 2024 · Review DOIPubMed 39475082Full text
  59. Mild Crohn's Disease: Definition and Management Claytor J, Kumar P, Ananthakrishnan AN, et al. · Current gastroenterology reports · 2023 · Review DOIPubMed 36753033
  60. Global evolution of inflammatory bowel disease across epidemiologic stages Hracs L, Windsor JW, Gorospe J, et al. · Nature · 2025 · Journal article DOIPubMed 40307548Full text

This page was translated automatically from English. The citations and numbers are unchanged. Read the English original if anything reads oddly. Read the English original